CA
NZ
UK
AU
IND
US
Shares of Vogenx (NASDAQ:VOGX) jumped as traders crowded into the newly public biopharmaceutical company, which began trading on theNasdaqCapital Market only days earlier. The move extends theVolatilitythat often follows a small biotech IPO, as the market works to price a clinical-stage company with no …
Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) jumped about 17%, as investors circled back to a clinical-stage cell-therapy company whose lead CAR-T program for aggressive lymphoma has been generating steady momentum. The move fits a familiar pattern in small-cap biotech, where sentiment around a maturing …
Shares of Lexaria Bioscience (NASDAQ:LEXX) rallied as investors piled back into the small-cap drug-delivery company on news that it is expanding its reach in the red-hot GLP-1 market. The move added Lexaria to the list of speculative small caps drawing attention in mid-August 2026, …
Owlet, Inc. (NYSE: OWLT) announced Q2 revenue grew 29.9% to a record $33.9 million, driven by 130,000 Owlet 360 subscribers and global expansion.
Akari Therapeutics plc (NASDAQ: AKTX) revealed preclinical findings for AKTX-101 showing notable tumor growth suppression in urothelial cancer.
Skye Bioscience, Inc. (NASDAQ: SKYE) shares closed down 14% at $0.36 after the company announced its merger with Redx Pharma to create Fibrx Therapeutics, a Nasdaq-listed fibrosis company led by Redx.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares closed down 12% at $1.46 despite the company receiving conditional FDA acceptance for CIFBEZY as the brand name for ibezapolstat, alongside a USPTO trademark allowance.
Ainos, Inc. (NASDAQ: AIMD) debuted its second-generation AI Nose platform, featuring comprehensive software, firmware, and edge computing enhancements aimed at stabilizing its AI-driven chemical sensing for persistent real-world use.
Psyence Biomedical Ltd. (NASDAQ: PBM) shares closed up 24% at $4.42 following President Trump's commitment to broaden ibogaine research and Right to Try access.
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported significant insider buying activity, with CEO Jayson Rieger acquiring 25,000 shares at a value of approximately $125,750.
Please wait processing your request...